Evaluation of cross-protection afforded by a Salmonella Choleraesuis vaccine against Salmonella infections in pigs under field conditions
Is Version Of
The SafePork conference series began in 1996 to bring together international researchers, industry, and government agencies to discuss current Salmonella research and identify research needs pertaining to both pig and pork production. In subsequent years topics of research presented at these conferences expanded to include other chemical and biological hazards to pig and pork production.
This field study investigated the efficacy of a Salmonella Choleraesuis live vaccine (Argus SC™) to reduce the number of infections with Salmonella. Twelve groups of about 380 pigs each were randomly allocated to either vaccination (V) or no vaccination (C). The vaccine was applied orally at 3 and 16 weeks. Forty pigs per group were blood sampled at 3, 10, 16 and 24 weeks to detect possible antibodies against Salmonella. The prevalence of Salmonella in the lymph nodes as the major variable. In the V groups, only 0.6 % of the lymph nodes was positive, whereas 7.2 % was positive in the C groups (p < 0.001). The percentage of seropositive pigs at 24 weeks (cut-off OD > 10) was 26 % and 9 % in the V and C groups, respectively (p < 0.00 I). The present study documented that vaccination with a live modified S. Choleraesuis vaccine is a useful tool to lower the prevalence of Salmonella in swine herds.